1 / 17

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate?

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate?. Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH July 18, 2011. Controlling and Ultimately Ending the HIV/AIDS Pandemic. Aggressively “seek, test and treat” infected individuals

herman
Download Presentation

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH July 18, 2011

  2. Controlling and Ultimately Ending the HIV/AIDS Pandemic • Aggressively “seek, test and treat” infected individuals • Prevent new infections • “Cure” existing infections

  3. FEM-PrEP HIV Prevention Study • Phase II trial testing effectiveness of oral Truvada among • HIV-uninfected women • The Independent Data Monitoring Committee (IDMC) advised that the study reached futility • Conducted in Kenya, South Africa and Tanzania • Funded by USAID, with early support from • Gates Foundation • Conducted by Family Health International • Full data (including drug levels) will be available later this year

  4. July 13, 2011 Landmark Study Finds Antiretroviral Drugs Highly Effective at Preventing HIV in Both Men and Women July 13, 2011 CDC Trial and Another Major Study Find PrEP Can Reduce Risk of HIV Infection Among Heterosexuals

  5. VOICE:Vaginal&OralInterventionstoControltheEpidemic Objectives: • Estimate the effectiveness of daily tenofovir 1% gel, oral TDF, and oral FTC/TDF in preventing HIV in women • Evaluate the extended safety of daily tenofovir 1% gel, oral TDF, and oral FTC/TDF in preventing HIV in women • Evaluate adherence and acceptability to the daily vaginal and oral regiments • Assess the selection of HIV-1 drug resistance in women acquiring HIV-1 in the study

  6. VOICE Study Design 5000 women, 1000 in each group Oral TDF 1:1:1 Oral Arm Oral Truvada Oral Placebo 3:2 1% Tenofovir Gel 1:1 Topical Arm Placebo Gel

  7. iPrEX OLE and San Francisco PrEP Demonstration Project • iPrEX Open Label Extension Study: Assessing adherence, drug levels and risk taking in a well-characterized cohort of trial participants after they are informed regarding the safety and efficacy of FTC/TDF PrEP and offered free open-label dosing • San Francisco PrEP Demonstration Project: Evaluating acceptability, uptake and adherence to daily PrEP among high-risk MSM in non-research settings and assessing risk behaviors before and after access to PrEP

  8. Additional PrEP Trials • HPTN 066: Phase I, randomized, open label, pharmacokinetic study to describe the dose-proportionality and intra-individual variability of tenofovirdiphosphate and emtricitabinetriphosphate at steady-state in healthy volunteers taking Truvada • HPTN 067: Phase II, randomized, open label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovirdisoproxilfumaratePrEP • HPTN 069: Phase II, randomized, double-blind, controlled four arm study of the safety, tolerability and adherence of maraviroc, maraviroc + emtricitabine, maraviroc + tenofovir, or tenofovir/emtricitabine for PrEP to prevent HIV in at-risk MSM (co-sponsored with the AIDS Clinical Trials Group)

  9. Additional Microbicide Trials • CHOICE – Emerging from VOICE • Dapivirine ring study, MTN 020 • MTN-013 – Phase I safety and pharmacokinetics of dapivirine/maravirocintravaginal ring • Tenofovir safety studies in special populations

  10. Next Steps – ARVs as Prevention

  11. Next Steps for PrEP and Microbicides • Adjust VOICE based upon Partners PrEP outcomes • Move 1% Tenofovir gel to licensure • Sensitivity to adherence of the activity of PrEP for heterosexual transmission • Continue development of rectal microbicides • Define role of current products in comprehensive prevention packages • Define adherence strategies, delivery systems, and approaches to social marketing

  12. The Dynamic Tension in the Prevention Field • Given the efficacy of treatment as prevention, what is the future niche for PrEP and microbicides in comprehensive prevention? • Do we seek to optimize what we have shown to be effective or do we seek a better next generation? • Current products are strikingly behaviorally dependent—adherence is a significant issue. • Can long acting formulations be devised—improving both treatment outcomes as well as prevention • Rings, implants, injectibles, long acting oral formulations

  13. Optimistic, Long Range Vision • The therapeutic armamentarium will continue to improve with development and roll out of ART requiring 4-12 doses per year • PrEP would then also require 4-12 doses a year • These would be tools that can control and start ending the HIV pandemic

More Related